Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KV Pharmaceutical Cleared To Resume Some Drug Shipments, But Cash Crisis Looms

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA gives go-ahead for the beleaguered company to ship two potassium chloride formulations following a satisfactory GMP inspection in August.

You may also be interested in...



KV Emerging From Bankruptcy As Makena Sales Pick Up Steam

KV clears major hurdle as court okays its chapter 11 reorganization plan, which provides for payment of $23.4 million owed under 2010 Department of Justice settlement and $231.4 million for senior notes; firm’s future remains tied to Makena.

KV's Gestiva Reemerges With New Name, Makena, And A Long-Sought FDA Approval

Approval of the pre-term birth prevention therapy could pull KV Pharmaceutical back from the brink.

KV's Gestiva Reemerges With New Name, Makena, And A Long-Sought FDA Approval

Approval of the pre-term birth prevention therapy could pull KV Pharmaceutical back from the brink.

Related Content

Topics

UsernamePublicRestriction

Register

PS071156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel